CY1115354T1 - Ενωσεις πεγκυλιωμενης ινσουλινης lispro - Google Patents
Ενωσεις πεγκυλιωμενης ινσουλινης lisproInfo
- Publication number
- CY1115354T1 CY1115354T1 CY20141100472T CY141100472T CY1115354T1 CY 1115354 T1 CY1115354 T1 CY 1115354T1 CY 20141100472 T CY20141100472 T CY 20141100472T CY 141100472 T CY141100472 T CY 141100472T CY 1115354 T1 CY1115354 T1 CY 1115354T1
- Authority
- CY
- Cyprus
- Prior art keywords
- lispro
- consulated
- relates
- insulation units
- pegylated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
Abstract
Η παρούσα εφεύρεση αναφέρεται στο πεδίο του διαβήτη. Ειδικότερα, η εφεύρεση αφορά σε ενώσεις πεγκυλιωμένης ινσουλίνης lispro που πεγκυλιώνονται με υψηλού μοριακού βάρους πολύ(αιθυλενογλυκόλη), είναι ιδιαίτερα διαλυτές σε φυσιολογικό pΗ, έχουν μια εκτεταμένη διάρκεια δράσης και χαρακτηρίζονται από φαρμακοκινητικούς, φαρμακοδυναμικούς, ή/και αιχμής-κοιλιάς λόγους μικρότερους από 2. Η εφεύρεση αφορά επίσης σε μεθόδους παροχής αυτών των μορίων, σε φαρμακευτικές συνθέσεις που τα περιέχουν και στις θεραπευτικές χρήσεις τους.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6128108P | 2008-06-13 | 2008-06-13 | |
US12139408P | 2008-12-10 | 2008-12-10 | |
EP12158390.0A EP2476430B1 (en) | 2008-06-13 | 2009-06-09 | Pegylated insulin lispro compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115354T1 true CY1115354T1 (el) | 2017-01-04 |
Family
ID=41110836
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100478T CY1112977T1 (el) | 2008-06-13 | 2012-05-25 | Ενωσεις πεγκυλιωμενης ινσουλινης lispro |
CY20141100472T CY1115354T1 (el) | 2008-06-13 | 2014-06-26 | Ενωσεις πεγκυλιωμενης ινσουλινης lispro |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100478T CY1112977T1 (el) | 2008-06-13 | 2012-05-25 | Ενωσεις πεγκυλιωμενης ινσουλινης lispro |
Country Status (34)
Country | Link |
---|---|
US (3) | US9050371B2 (el) |
EP (2) | EP2476430B1 (el) |
JP (2) | JP4890662B2 (el) |
KR (1) | KR101238979B1 (el) |
CN (1) | CN102065884B (el) |
AR (1) | AR071990A1 (el) |
AT (1) | ATE554786T1 (el) |
AU (1) | AU2009257597B2 (el) |
BR (1) | BRPI0915838A2 (el) |
CA (1) | CA2727825C (el) |
CL (1) | CL2009001340A1 (el) |
CO (1) | CO6331292A2 (el) |
CY (2) | CY1112977T1 (el) |
DK (2) | DK2288375T3 (el) |
DO (1) | DOP2010000379A (el) |
EA (1) | EA028657B1 (el) |
EC (1) | ECSP10010677A (el) |
ES (2) | ES2473580T3 (el) |
HK (2) | HK1170659A1 (el) |
HR (2) | HRP20120397T1 (el) |
IL (1) | IL209265A (el) |
JO (1) | JO2932B1 (el) |
MA (1) | MA32394B1 (el) |
MX (1) | MX2010013837A (el) |
MY (1) | MY158890A (el) |
NZ (1) | NZ588997A (el) |
PE (2) | PE20091960A1 (el) |
PL (2) | PL2288375T3 (el) |
PT (2) | PT2288375E (el) |
RS (1) | RS52361B (el) |
SI (2) | SI2288375T1 (el) |
TW (1) | TWI451876B (el) |
WO (1) | WO2009152128A1 (el) |
ZA (1) | ZA201008174B (el) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0413276B8 (pt) * | 2003-08-05 | 2021-05-25 | Novo Nordisk As | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica |
EP2505593A1 (en) | 2005-12-28 | 2012-10-03 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
WO2008152106A1 (en) * | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
WO2009115469A1 (en) | 2008-03-18 | 2009-09-24 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
WO2010043566A2 (de) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem insulin und einem glp-1-agonisten |
ES2607003T3 (es) * | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria |
EP2370459A1 (en) | 2008-12-15 | 2011-10-05 | Zealand Pharma A/S | Glucagon analogues |
CN102282166B (zh) | 2008-12-15 | 2015-04-01 | 西兰制药公司 | 胰高血糖素类似物 |
DK2370462T3 (da) | 2008-12-15 | 2014-09-08 | Zealand Pharma As | Glucagon-analoger |
EA020520B1 (ru) | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
SG177609A1 (en) | 2009-07-13 | 2012-02-28 | Zealand Pharma As | Acylated glucagon analogues |
US8454956B2 (en) * | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
ES2855146T3 (es) | 2009-11-13 | 2021-09-23 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
EP3708190A1 (en) | 2010-02-26 | 2020-09-16 | Novo Nordisk A/S | Stable antibody containing compositions |
AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
US9981017B2 (en) | 2010-04-02 | 2018-05-29 | Hanmi Science Co., Ltd. | Insulin conjugate using an immunoglobulin fragment |
DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
WO2011141407A1 (en) * | 2010-05-10 | 2011-11-17 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
US8637458B2 (en) * | 2010-05-12 | 2014-01-28 | Biodel Inc. | Insulin with a stable basal release profile |
US9878012B2 (en) * | 2010-05-18 | 2018-01-30 | Neumedicines, Inc. | IL-12 formulations for enhancing hematopoiesis |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
US20130136733A1 (en) * | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
MX2012014961A (es) | 2010-06-24 | 2013-02-26 | Zealand Pharma As | Analogos de glucagon. |
EA201991014A1 (ru) | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение диабета |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
PT2611458T (pt) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2 |
ES2737960T3 (es) | 2010-10-01 | 2020-01-17 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos |
RU2013123515A (ru) | 2010-10-27 | 2014-12-10 | Ново Нордиск А/С | Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами |
US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
CA3065178C (en) | 2010-12-13 | 2022-02-01 | Quiapeg Pharmaceuticals Ab | Functionalized polymers |
UY33872A (es) | 2011-01-20 | 2012-08-31 | Zealand Pharma As | Uso de análogos de glucagón acilados |
CN102675452B (zh) * | 2011-03-17 | 2015-09-16 | 重庆富进生物医药有限公司 | 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物 |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
SG195192A1 (en) * | 2011-06-02 | 2013-12-30 | Hanmi Science Co Ltd | Non-peptidyl polymer-insulin multimer and method for producing the same |
EP2720712B1 (en) * | 2011-06-17 | 2016-03-02 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
EP3053590A1 (fr) * | 2011-08-10 | 2016-08-10 | Adocia | Solution injectable d'au moins une insuline basale |
PT2750699E (pt) | 2011-08-29 | 2015-11-03 | Sanofi Aventis Deutschland | Acelerómetro pendular |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
IN2014MN02304A (el) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
AR090843A1 (es) * | 2012-05-09 | 2014-12-10 | Lilly Co Eli | Tratamiento para diabetes comorbida con enfermedad renal cronica |
MX349035B (es) | 2012-05-17 | 2017-07-07 | Extend Biosciences Inc | Portadores para el suministro mejorado de farmaco. |
EP3628332A1 (en) | 2012-06-12 | 2020-04-01 | QuiaPEG Pharmaceuticals AB | Conjugates of biologically active molecules to functionalized polymers |
WO2014015133A1 (en) | 2012-07-19 | 2014-01-23 | National Cheng Kung University | Treatment of osteoarthritis using il-20 antagonists |
AR091866A1 (es) | 2012-07-23 | 2015-03-04 | Zealand Pharma As | Analogos del glucagon |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
US9700599B2 (en) * | 2012-11-13 | 2017-07-11 | Adocia | Rapid-acting insulin formulation comprising a substituted anionic compound |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
US10421795B2 (en) | 2012-12-17 | 2019-09-24 | Merck Sharp & Dohme Corp. | Process for purifying insulin and analogues thereof |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
CA2907848A1 (en) | 2013-04-03 | 2014-10-09 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
UA122767C2 (uk) | 2013-10-17 | 2021-01-06 | Зіленд Фарма А/С | Ацильований аналог глюкагону |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
CA2929459C (en) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
CN105092490B (zh) * | 2014-05-04 | 2019-08-09 | 重庆派金生物科技有限公司 | 人胰岛素及类似物或偶联物体外生物活性测定方法 |
US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
BR112017008659A2 (pt) | 2014-10-29 | 2018-01-30 | Zealand Pharma As | ?métodos e compostos de agonista de gip? |
CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
US9808011B2 (en) | 2014-12-15 | 2017-11-07 | Biovectra Inc. | Pentacyclic triterpene compounds and uses thereof |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
AU2016247499B2 (en) | 2015-04-16 | 2020-09-03 | Zealand Pharma A/S | Acylated glucagon analogue |
JO3749B1 (ar) * | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
AR107560A1 (es) | 2016-02-24 | 2018-05-09 | Lilly Co Eli | Compuesto que disminuye la glucosa en la sangre |
HUE055231T2 (hu) | 2016-12-16 | 2021-11-29 | Novo Nordisk As | Inzulint tartalmazó gyógyászati készítmények |
WO2018153506A1 (en) * | 2017-02-22 | 2018-08-30 | Adocia | Fast-acting insulin composition comprising a citric acid salt |
EP3592393B1 (en) | 2017-03-10 | 2021-12-01 | QuiaPEG Pharmaceuticals AB | Releasable conjugates |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
FR3084585B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes |
JP2021535920A (ja) | 2018-09-12 | 2021-12-23 | キアペグ ファーマシューティカルズ アクチエボラグ | 放出可能なglp−1コンジュゲート |
CN113801236A (zh) * | 2020-06-11 | 2021-12-17 | 宁波鲲鹏生物科技有限公司 | 一种赖脯胰岛素的制备方法 |
WO2023225534A1 (en) | 2022-05-18 | 2023-11-23 | Protomer Technologies Inc. | Aromatic boron-containing compounds and related insulin analogs |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DK347086D0 (da) | 1986-07-21 | 1986-07-21 | Novo Industri As | Novel peptides |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
IE62879B1 (en) | 1987-02-25 | 1995-03-08 | Novo Nordisk As | Novel insulin derivatives |
US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
ATE204882T1 (de) | 1993-09-17 | 2001-09-15 | Novo Nordisk As | Acyliertes insulin |
US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
US6251856B1 (en) | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
ZA984697B (en) | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
DE69924232D1 (de) | 1998-01-09 | 2005-04-21 | Novo Nordisk As | Stabilisierte insulin-zubereitungen |
DK1121144T3 (da) * | 1998-10-16 | 2002-09-23 | Novo Nordisk As | Stabile koncentrerede insulinpræparater til pulmonar indgivelse |
WO2001052937A1 (en) * | 2000-01-24 | 2001-07-26 | Medtronic Minimed, Inc. | Mixed buffer system for stabilizing polypeptide formulations |
WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
BR0209896A (pt) * | 2001-05-21 | 2004-08-17 | Nektar Therapeutics | Composição de insulina para administração pulmonar, e, métodos para suprir insulina a um indivìduo mamìfero, para prover uma composição de insulina não-imunogênica e uma composição de insulina de efeito prolongado para administração ao pulmão de um indivìduo |
US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
EP1545460A4 (en) * | 2001-12-20 | 2005-11-16 | Lilly Co Eli | INSULIN MOLECULE WITH TEMPORARY EFFECT |
CA2843439A1 (en) * | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd | Reversible pegylated drugs |
US9040664B2 (en) | 2003-04-11 | 2015-05-26 | Antriabio, Inc. | Materials and methods for preparing protein-polymer conjugates |
ES2442223T3 (es) | 2004-08-31 | 2014-02-10 | Novo Nordisk A/S | Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas |
US20060045866A1 (en) | 2004-09-01 | 2006-03-02 | Chris Chappelow | Novel high purity and high molecular weight mPEG alcohol compositions |
US7199193B2 (en) | 2004-09-28 | 2007-04-03 | Dow Global Technologies, Inc. | Polyethylene glycol compounds and process of making |
JP4785206B2 (ja) * | 2005-01-14 | 2011-10-05 | ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド | 修飾されたエキセンディン(Exendins)及びその使用 |
EP1843790A2 (en) | 2005-01-27 | 2007-10-17 | Novo Nordisk A/S | Insulin derivatives conjugated with structurally well defined branched polymers |
US7824919B2 (en) | 2005-03-04 | 2010-11-02 | Dr. Reddy's Laboratories Limited | Method for analyzing activated polyethylene glycol compounds |
US20100216690A1 (en) * | 2005-03-18 | 2010-08-26 | Novo Nordisk A/S | Pegylated Single-Chain Insulin |
WO2006124529A1 (en) * | 2005-05-13 | 2006-11-23 | Eli Lilly And Company | Glp-1 pegylated compounds |
JP5096363B2 (ja) * | 2005-12-16 | 2012-12-12 | ネクター セラピューティックス | Glp−1のポリマ複合体 |
ES2542146T3 (es) * | 2006-07-31 | 2015-07-31 | Novo Nordisk A/S | Insulinas extendidas PEGiladas. |
WO2008084051A1 (en) | 2007-01-12 | 2008-07-17 | Novo Nordisk A/S | Mixtures of pegylated insulin and fast acting insulin for pulmonary administration |
TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
-
2009
- 2009-05-26 TW TW098117491A patent/TWI451876B/zh active
- 2009-05-31 JO JO2009195A patent/JO2932B1/en active
- 2009-06-02 AR ARP090101981A patent/AR071990A1/es unknown
- 2009-06-02 CL CL2009001340A patent/CL2009001340A1/es unknown
- 2009-06-02 PE PE2009000763A patent/PE20091960A1/es not_active Application Discontinuation
- 2009-06-02 PE PE2014000431A patent/PE20140974A1/es active IP Right Grant
- 2009-06-09 AU AU2009257597A patent/AU2009257597B2/en not_active Ceased
- 2009-06-09 SI SI200930263T patent/SI2288375T1/sl unknown
- 2009-06-09 DK DK09763419.0T patent/DK2288375T3/da active
- 2009-06-09 US US12/481,111 patent/US9050371B2/en not_active Expired - Fee Related
- 2009-06-09 WO PCT/US2009/046704 patent/WO2009152128A1/en active Application Filing
- 2009-06-09 EP EP12158390.0A patent/EP2476430B1/en active Active
- 2009-06-09 EP EP09763419A patent/EP2288375B1/en active Active
- 2009-06-09 ES ES12158390.0T patent/ES2473580T3/es active Active
- 2009-06-09 DK DK12158390.0T patent/DK2476430T3/da active
- 2009-06-09 CA CA2727825A patent/CA2727825C/en not_active Expired - Fee Related
- 2009-06-09 KR KR1020107027792A patent/KR101238979B1/ko not_active IP Right Cessation
- 2009-06-09 PT PT09763419T patent/PT2288375E/pt unknown
- 2009-06-09 EA EA201170020A patent/EA028657B1/ru not_active IP Right Cessation
- 2009-06-09 ES ES09763419T patent/ES2383496T3/es active Active
- 2009-06-09 MX MX2010013837A patent/MX2010013837A/es active IP Right Grant
- 2009-06-09 RS RS20120241A patent/RS52361B/en unknown
- 2009-06-09 CN CN200980122164.9A patent/CN102065884B/zh not_active Expired - Fee Related
- 2009-06-09 PT PT121583900T patent/PT2476430E/pt unknown
- 2009-06-09 MY MYPI2010005892A patent/MY158890A/en unknown
- 2009-06-09 SI SI200930944T patent/SI2476430T1/sl unknown
- 2009-06-09 NZ NZ588997A patent/NZ588997A/en not_active IP Right Cessation
- 2009-06-09 PL PL09763419T patent/PL2288375T3/pl unknown
- 2009-06-09 JP JP2011513625A patent/JP4890662B2/ja not_active Expired - Fee Related
- 2009-06-09 BR BRPI0915838A patent/BRPI0915838A2/pt not_active Application Discontinuation
- 2009-06-09 AT AT09763419T patent/ATE554786T1/de active
- 2009-06-09 US US12/997,254 patent/US20110105392A1/en not_active Abandoned
- 2009-06-09 PL PL12158390T patent/PL2476430T3/pl unknown
-
2010
- 2010-11-11 IL IL209265A patent/IL209265A/en not_active IP Right Cessation
- 2010-11-15 ZA ZA2010/08174A patent/ZA201008174B/en unknown
- 2010-12-07 DO DO2010000379A patent/DOP2010000379A/es unknown
- 2010-12-13 EC EC2010010677A patent/ECSP10010677A/es unknown
- 2010-12-13 MA MA33425A patent/MA32394B1/fr unknown
- 2010-12-22 CO CO10160886A patent/CO6331292A2/es not_active Application Discontinuation
-
2011
- 2011-04-19 HK HK12111374.9A patent/HK1170659A1/xx not_active IP Right Cessation
- 2011-04-19 HK HK11103936.8A patent/HK1149713A1/xx not_active IP Right Cessation
- 2011-12-14 JP JP2011273593A patent/JP5336572B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-11 HR HRP20120397AT patent/HRP20120397T1/hr unknown
- 2012-05-25 CY CY20121100478T patent/CY1112977T1/el unknown
-
2014
- 2014-05-28 HR HRP20140480AT patent/HRP20140480T1/hr unknown
- 2014-06-26 CY CY20141100472T patent/CY1115354T1/el unknown
-
2015
- 2015-05-01 US US14/701,921 patent/US20150297681A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115354T1 (el) | Ενωσεις πεγκυλιωμενης ινσουλινης lispro | |
CY1124659T1 (el) | Προϊοντα συζευξης ενος τμηματος il-2 και ενος πολυμερους | |
CY1122218T1 (el) | Αλατα και πολυμορφα της 8-φθορο-2-{4-[(μεθυλαμινο)μεθυλο]φαινυλο}-1,3,4,5-τετραϋδρο-6η-αζεπινο[5,4,3-cd]ινδολο-6-ονης | |
CY1117312T1 (el) | Θεραπευτικη αγωγη συνουκλεϊνοπαθειων | |
CY1120670T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi) | |
CY1120641T1 (el) | Βελτιωμενο σκευασμα λιπιδιων | |
CY1119387T1 (el) | Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου | |
CY1123649T1 (el) | Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη | |
MX2021008463A (es) | Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco. | |
CY1114737T1 (el) | Παραγωγα κινοξαλινδιονης | |
CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
EA201690744A1 (ru) | Конъюгаты белок-полимер-лекарственное средство | |
CY1121125T1 (el) | Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης | |
CU23556A1 (es) | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico | |
EA201491441A1 (ru) | Композиции конъюгата xten и способы их получения | |
MX2011009808A (es) | Agentes de elaboracion de imagen optica. | |
CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) | |
BR112013011282A2 (pt) | formulações baseadas em ácido hialurônico | |
UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
CY1110419T1 (el) | Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ | |
WO2009112488A3 (en) | Polyether polyol dendron conjugates with effector molecules for biological targeting | |
CY1114874T1 (el) | Παραγωγα σπιρο-ινδολης για τη θεραπεια παρασιτικων νοσων | |
MY158228A (en) | Factor ix conjugates with extended half-lives | |
CY1114960T1 (el) | Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου | |
EA201270419A1 (ru) | Пролекарства гуанфацина |